Health Diagnostics

Prevencio Announces U.S. Patent Issuance for ML-riven Blood Test

HART CVE test provides highly accurate prediction of one-year risk for heart attack, stroke, or cardiac death

Prevencio, Inc. today announces the United States Patent Office’s issuance of a patent for its highly accurate blood test, HART CVE, for a patient’s one-year risk of heart attack, stroke, or cardiovascular death. The company leveraged its’ Artificial Intelligence (AI)-driven HART platform and expertise in cardiac blood tests to develop HART CVE.

“Prevencio is pleased with the continued development of our patent portfolio. This patent issuance for HART CVE demonstrates the U.S. Patent Office’s recognition of our novel invention for a machine learning-driven, multiple protein, algorithmically scored blood test for detection of adverse cardiac events,” said Rhonda Rhyne, President and Chief Executive Officer of Prevencio.

The company recently announced an international 1,500+ patient study using HART CVE. When the HART CVE test score was divided into low-risk and high-risk categories, the test predicted with 98% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year.

“This AI-powered risk score test provides improved accuracy as compared to clinical risk factors and single protein tests. The test could be particularly useful for patients with suspected or known stable and acute heart disease, for which there are very few prognostic risk models,” said James L. Januzzi, MD, a practicing cardiologist at Massachusetts General Hospital, Professor of Medicine at Harvard Medical School and Principal Investigator in development, validation, and ongoing testing of the HART CVE test. “In addition to leading to more appropriate care of patients, it is well-suited for a role in ‘enriching’ pharmaceutical cardiac clinical trials, which could lead to lower trial costs and reduced time to complete clinical trials.”

Cardiovascular disease is the leading cause of death in the U.S. and globally. According to the American Heart Association (AHA), the U.S. spends approximately $316 billion annually on cardiovascular disease and stroke, or approximately 10% of the $3.2 trillion spent on total healthcare. By 2030, AHA projects that more than 40% of the U.S. adult population will have cardiovascular disease, with healthcare-related expenditures of $1 trillion.

In addition to the HART CVE test for one-year risk of a cardiac event, Prevencio has recently launched a second multi-protein blood test, HART CADhs, for diagnosing obstruction of the heart arteries. HART CADhs was shown to be more accurate (86% AUC accuracy) than standard-of-care stress tests (52% AUC accuracy). HART CVE and HART CADhs tests are currently available to medical professionals for patient use. For additional information, visit Prevencio, Inc.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

Dermatologic Diagnostics Co. Castle Biosciences Presents New Data

Business Wire

Healthtech Curi Bio Raises $6M for iPSC-derived Predictive Platforms

PR Newswire

Diagnostic Tech Provider Tesseract Health Closes Oversubscribed $80M

Business Wire